In this issue:
ARPI and taxanes in mCRPC
Prostate radiotherapy in de novo mHSPC
Physician reasons for or against treatment intensification in mHSPC
Overtreatment among men with limited longevity
Darolutamide + ADT in mHSPC
Durvalumab +/- tremelimumab for mCRPC
MRI-based screening in carriers of pathogenic germline mutations
Reduced vs standard enzalutamide and adverse events in frail patients
Radical prostatectomy in men with high-risk HSPC
Helical tomotherapy vs 3-D conformal radiation therapy
Please login below to download this issue (PDF)